Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yumanity Therapeutics

yumanity.com

Latest From Yumanity Therapeutics

Former Gilead CSO Bischofberger Lands At Kronos As C-Suite Moves To Start-Ups Continue

Norbert Bischofberger returns to his start-up roots, exiting Gilead after nearly 30 years to become CEO of Kronos, which is developing novel drugs directed at tough cancer targets. He's one of several big pharma/large biotech executives to venture recently into entrepreneurial opportunities.

Financing Leadership

Where Will CNS Drug Development Go In 2018?

The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.

Neurology Business Strategies

Appointments: Sanofi, Regeneron, Galena, Genmab, Abpro and Myokardia

This week's roundup sees Sanofi appoint Biogen's former SVP of corporate affairs to executive vice president, external affairs. Meanwhile, Galena Biopharma, Abpro, Genmab and Purdue Pharma have all named new executives.

Appointments

Tech Transfer Deals, July 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Yumanity Therapeutics
  • Senior Management
  • Richard Peters, MD, PhD, CEO
    Paulash Mohsen, CBO
    Kenneth Rhodes, PhD, CSO
    Marie Epstein, VP, Fin.
  • Contact Info
  • Yumanity Therapeutics
    Phone: (617) 409-5300
    790 Memorial Dr.
    Ste. 2C
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register